145 related articles for article (PubMed ID: 29491084)
21. Dual targeting of mTOR and aurora-A kinase for the treatment of uterine Leiomyosarcoma.
Brewer Savannah KJ; Demicco EG; Lusby K; Ghadimi MP; Belousov R; Young E; Zhang Y; Huang KL; Lazar AJ; Hunt KK; Pollock RE; Creighton CJ; Anderson ML; Lev D
Clin Cancer Res; 2012 Sep; 18(17):4633-45. PubMed ID: 22821997
[TBL] [Abstract][Full Text] [Related]
22. p53, epidermal growth factor, and platelet-derived growth factor in uterine leiomyosarcoma and leiomyomas.
Anderson SE; Nonaka D; Chuai S; Olshen AB; Chi D; Sabbatini P; Soslow RA
Int J Gynecol Cancer; 2006; 16(2):849-53. PubMed ID: 16681772
[TBL] [Abstract][Full Text] [Related]
23. Prognostic role of plasma fibrinogen in patients with uterine leiomyosarcoma - a multicenter study.
Bekos C; Grimm C; Brodowicz T; Petru E; Hefler L; Reimer D; Koch H; Reinthaller A; Polterauer S; Polterauer M
Sci Rep; 2017 Nov; 7(1):14474. PubMed ID: 29101329
[TBL] [Abstract][Full Text] [Related]
24. Potential Targets' Analysis Reveals Dual PI3K/mTOR Pathway Inhibition as a Promising Therapeutic Strategy for Uterine Leiomyosarcomas-an ENITEC Group Initiative.
Cuppens T; Annibali D; Coosemans A; Trovik J; Ter Haar N; Colas E; Garcia-Jimenez A; Van de Vijver K; Kruitwagen RP; Brinkhuis M; Zikan M; Dundr P; Huvila J; Carpén O; Haybaeck J; Moinfar F; Salvesen HB; Stukan M; Mestdagh C; Zweemer RP; Massuger LF; Mallmann MR; Wardelmann E; Mints M; Verbist G; Thomas D; Gommé E; Hermans E; Moerman P; Bosse T; Amant F
Clin Cancer Res; 2017 Mar; 23(5):1274-1285. PubMed ID: 28232476
[No Abstract] [Full Text] [Related]
25. A differentiation-based microRNA signature identifies leiomyosarcoma as a mesenchymal stem cell-related malignancy.
Danielson LS; Menendez S; Attolini CS; Guijarro MV; Bisogna M; Wei J; Socci ND; Levine DA; Michor F; Hernando E
Am J Pathol; 2010 Aug; 177(2):908-17. PubMed ID: 20558575
[TBL] [Abstract][Full Text] [Related]
26. A small-molecule inhibitor targeting the mitotic spindle checkpoint impairs the growth of uterine leiomyosarcoma.
Shan W; Akinfenwa PY; Savannah KB; Kolomeyevskaya N; Laucirica R; Thomas DG; Odunsi K; Creighton CJ; Lev DC; Anderson ML
Clin Cancer Res; 2012 Jun; 18(12):3352-65. PubMed ID: 22535157
[TBL] [Abstract][Full Text] [Related]
27. Elimusertib (BAY1895344), a novel ATR inhibitor, demonstrates in vivo activity in ATRX mutated models of uterine leiomyosarcoma.
Harold J; Bellone S; Manavella DD; Mutlu L; McNamara B; Hartwich TMP; Zipponi M; Yang-Hartwich Y; Demirkiran C; Verzosa MS; Choi J; Dong W; Buza N; Hui P; Altwerger G; Huang GS; Andikyan V; Clark M; Ratner E; Azodi M; Schwartz PE; Santin AD
Gynecol Oncol; 2023 Jan; 168():157-165. PubMed ID: 36442427
[TBL] [Abstract][Full Text] [Related]
28. Molecular subtypes of uterine leiomyosarcoma and correlation with clinical outcome.
Barlin JN; Zhou QC; Leitao MM; Bisogna M; Olvera N; Shih KK; Jacobsen A; Schultz N; Tap WD; Hensley ML; Schwartz GK; Boyd J; Qin LX; Levine DA
Neoplasia; 2015 Feb; 17(2):183-9. PubMed ID: 25748237
[TBL] [Abstract][Full Text] [Related]
29. Hepatocyte growth factor activator inhibitors (HAI-1 and HAI-2) are potential targets in uterine leiomyosarcoma.
Nakamura K; Abarzua F; Hongo A; Kodama J; Nasu Y; Kumon H; Hiramatsu Y
Int J Oncol; 2010 Sep; 37(3):605-14. PubMed ID: 20664929
[TBL] [Abstract][Full Text] [Related]
30. Uterine leiomyosarcomas harboring MAP2K4 gene amplification are sensitive in vivo to PLX8725, a novel MAP2K4 inhibitor.
McNamara B; Harold J; Manavella D; Bellone S; Mutlu L; Hartwich TMP; Zipponi M; Yang-Hartwich Y; Demirkiran C; Verzosa MSZ; Yang K; Choi J; Dong W; Buza N; Hui P; Altwerger G; Huang GS; Andikyan V; Clark M; Ratner E; Azodi M; Schwartz PE; Burton EA; Inagaki H; Albers A; Zhang C; Bollag G; Schlessinger J; Santin AD
Gynecol Oncol; 2023 May; 172():65-71. PubMed ID: 36958197
[TBL] [Abstract][Full Text] [Related]
31. Roles of Matrix Metalloproteinases 2 and 9 in Uterine Leiomyosarcoma.
Wang X; Li C; Lou L; Zhu H
Anticancer Res; 2024 Apr; 44(4):1465-1473. PubMed ID: 38537953
[TBL] [Abstract][Full Text] [Related]
32. A rare case of uterine leiomyosarcoma metastasis to the duodenum.
Patel JK; Cervellione KL; Sulh M; Patel AA; Gintautas J
Proc West Pharmacol Soc; 2009; 52():8-10. PubMed ID: 22128409
[TBL] [Abstract][Full Text] [Related]
33. Molecular differential analysis of uterine leiomyomas and leiomyosarcomas through weighted gene network and pathway tracing approaches.
Sahly NN; Banaganapalli B; Sahly AN; Aligiraigri AH; Nasser KK; Shinawi T; Mohammed A; Alamri AS; Bondagji N; Elango R; Shaik NA
Syst Biol Reprod Med; 2021 Jun; 67(3):209-220. PubMed ID: 33685300
[TBL] [Abstract][Full Text] [Related]
34. Novel therapeutic strategies targeting UCP2 in uterine leiomyosarcoma.
Nagao Y; Yokoi A; Yoshida K; Sugiyama M; Watanabe E; Nakamura K; Kitagawa M; Asano-Inami E; Koya Y; Yoshihara M; Tamauchi S; Shimizu Y; Ikeda Y; Yoshikawa N; Kato T; Yamamoto Y; Kajiyama H
Pharmacol Res; 2023 Mar; 189():106693. PubMed ID: 36773710
[TBL] [Abstract][Full Text] [Related]
35. [The loss of heterozygosity and microsatellite instability analysis in differential diagnostics of leiomyosarcoma and proliferative leiomyoma of the uterus].
Shikeeva AA; Kekeeva TV; Zavalishina LÉ; Andreeva IuIu; Frank GA
Arkh Patol; 2011; 73(4):47-50. PubMed ID: 22164433
[TBL] [Abstract][Full Text] [Related]
36. Distinctive outcome in patients with non-uterine and uterine leiomyosarcoma.
Lamm W; Natter C; Schur S; Köstler WJ; Reinthaller A; Krainer M; Grimm C; Horvath R; Amann G; Funovics P; Brodowicz T; Polterauer S
BMC Cancer; 2014 Dec; 14():981. PubMed ID: 25523155
[TBL] [Abstract][Full Text] [Related]
37.
de Almeida BC; Dos Anjos LG; Uno M; Cunha IWD; Soares FA; Baiocchi G; Baracat EC; Carvalho KC
Cells; 2019 Nov; 8(11):. PubMed ID: 31744257
[TBL] [Abstract][Full Text] [Related]
38. Analysis of p53-dependent mechanisms in the maintenance of genetic stability in diploid tumourigenic line SK-UT-1B of human uterine leiomyosarcoma.
Smirnova IS; Yakovleva TK; Rosanov YM; Aksenov ND; Pospelova TV
Cell Biol Int; 2001; 25(11):1101-15. PubMed ID: 11913954
[TBL] [Abstract][Full Text] [Related]
39. MicroRNA-137, an HMGA1 target, suppresses colorectal cancer cell invasion and metastasis in mice by directly targeting FMNL2.
Liang L; Li X; Zhang X; Lv Z; He G; Zhao W; Ren X; Li Y; Bian X; Liao W; Liu W; Yang G; Ding Y
Gastroenterology; 2013 Mar; 144(3):624-635.e4. PubMed ID: 23201162
[TBL] [Abstract][Full Text] [Related]
40. The role of adjuvant therapy in uterine leiomyosarcoma.
Ducie JA; Leitao MM
Expert Rev Anticancer Ther; 2016; 16(1):45-55. PubMed ID: 26558647
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
